icon-folder.gif   Conference Reports for NATAP  
 
  AASLD
The Liver Meeting
Boston MA
November 2016
Back grey_arrow_rt.gif
 
 
 
SVR12 rates under DAA-based HCV therapy from the National German Cohort Study: Does HIV co-infection impair the response to DAA combination therapy?
 
 
  Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
 
AASLD: Real World Effectiveness of Ledipasvir/Sofosbuvir in Patients Coinfected With HCV and HIV-1:A Comparative Analysis of Clinical Trials with Four Real World Cohorts - (11/14/16)
 
AASLD: Real-world Outcomes With New HCV Antivirals in HIV/HCV-coinfected Subjects:Madrid Coinfection Registry (Madrid-CoRE) Findings - (11/30/16)
 
IDWeek: Effectiveness of DAA Regimens in Genotype 1 HIV/HCV Coinfected Patients: An Analysis of the VA National Clinical Case Registry - (11/28/16)
 
AASLD: Ledipasvir/Sofosbuvir for 8 Weeks Results in High SVR Rates in Treatment-Na´ve Patients With Chronic HCV Infection and HIV/HCV Coinfection - in Russia - (11/17/16)

 
Jurgen K. Rockstroh1 Thomas Lutz2, Stefan Mauss3, Christiane Cordes4, Heribert Hillenbrand5, Arend Moll6, Heike Pfeiffer-Vornkahl7,
Markus Cornberg8, Michael P. Manns8, Axel Baumgarten9, German Hepatitis C-Registry10 1Department of Medicine I, University Hospital Bonn, Bonn, 2Infektiologikum, Frankfurt, 3Center for HIV and Hepatogastroenterology, Duesseldorf, 4Hepatologische Praxis, Berlin, 5PraxisCityOst, Berlin,
6Praxiszentrum Kaiserdamm, Berlin, 7e.factum GmbH, Butzbach, 8Hannover Medical School, Hannover, 9Center for infectious diseases, Berlin/Prenzlauer Berg, 10Leberstiftungs-GmbH Deutschland, Hannover

1214161

1214162

1214163